(Q53058794)

English

Phase II study of first-line (131)I-rituximab radioimmunotherapy in follicular non-Hodgkin lymphoma and prognostic (18)F-fluorodeoxyglucose positron emission tomography.

scientific article published on 19 August 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/25065701

Phase II study of first-line (131)I-rituximab radioimmunotherapy in follicular non-Hodgkin lymphoma and prognostic (18)F-fluorodeoxyglucose positron emission tomography. (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/25065701

non-Hodgkin lymphoma

1 reference

based on heuristic

inferred from title

author name string

Andrew D McQuillan

1

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/25065701

William B G Macdonald

2

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/25065701

J Harvey Turner

3

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/25065701

publication date

19 August 2014

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/25065701

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/25065701

56

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/25065701

5

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/25065701

1271-1277

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/25065701

Follicular lymphoma in the United States: first report of the national LymphoCare study

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.949260

21 January 2018

Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.949260

21 January 2018

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.949260

21 January 2018

Current role of FDG PET/CT in lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.949260

21 January 2018

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.949260

21 January 2018

Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.949260

21 January 2018

Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.949260

21 January 2018

Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.949260

21 January 2018

Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.949260

21 January 2018

Non-infectious pulmonary toxicity of rituximab: a systematic review

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.949260

21 January 2018

Functional decline in older patients with cancer receiving first-line chemotherapy

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.949260

21 January 2018

Fractionated ⁹⁰Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteria.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.949260

21 January 2018

Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.949260

21 January 2018

PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.949260

21 January 2018

Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.949260

21 January 2018

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.949260

21 January 2018

Report on the First International Workshop on Interim-PET-Scan in Lymphoma.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.949260

21 January 2018

Follicular lymphoma international prognostic index.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.949260

21 January 2018

FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.949260

21 January 2018

131I-Anti CD20 Radioimmunotherapy of Relapsed or Refractory Non-Hodgkins Lymphoma: A Phase II Clinical Trial of a Nonmyeloablative Dose Regimen of Chimeric Rituximab Radiolabeled in a Hospital

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.949260

21 January 2018

Outpatient 131I-rituximab radioimmunotherapy for non-Hodgkin lymphoma: a study in safety.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.949260

21 January 2018

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.949260

21 January 2018

Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.949260

21 January 2018

Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.949260

21 January 2018

Dissecting follicular lymphoma: high versus low risk

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.949260

21 January 2018

Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and G

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.949260

21 January 2018

FDG PET/CT predictive role in follicular lymphoma.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.949260

21 January 2018

High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.949260

21 January 2018

Repeat treatment with iodine-131-rituximab is safe and effective in patients with relapsed indolent B-cell non-Hodgkin's lymphoma who had previously responded to iodine-131-rituximab.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.949260

21 January 2018

Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposure

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.949260

21 January 2018

Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.949260

21 January 2018

Phase 1/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.949260

21 January 2018

Identifiers

10.3109/10428194.2014.949260

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/25065701

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/25065701

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53058794&oldid=1531956862"